Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients

• Published in: Blood 2009-11, Vol.114 (22), p.2284-2284
• Main Authors: Kim, Sung-Won, Yoon, Sung-Soo, Suzuki, Ritsuro, Yi, Hyeon Gyu, Ago, Hiroatsu, Imamura, Masahiro, Wake, Atsushi, Yoshida, Takashi, Lee, Je-Jung, Kim, Jin Seok, Maeda, Yoshinobu, Izutsu, Koji, Kang, Hye Jin, Lee, Je-Hwan, Kim, Hugh Chul, Suzumiya, Junji, Matsuno, Yoshihiro, Kim, Chul Woo, Nagafuji, Koji, Takaue, Yoichi, Harada, Mine, Kim, Chul Soo
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V114.22.2284.2284

Abstract 2284 Poster Board II-261 To evaluate the role of autologous and allogeneic SCT in the treatment of PTCLs, Japan Study Group for Cell Therapy and Transplantation conducted a multicenter retrospective survey in Japan and Korea. After excluding patients with adult T-cell leukemia/lymphoma and NK-cell tumors, patient data were newly collected from 330 patients (222 male and 108 female) with a median age of 49 years (range, 13–71) who underwent SCT between 9/1991 and 12/2008 (196 autologous and 134 allogeneic including 31 patients with previous autograft). Allogeneic SCT (53 BM, 54 PB, 1 BM+PB, 26 CB) was performed using a reduced-intensity conditioning (RIC) in 84 patients (63%). While a pathologic central review will be performed, currently there were 159 (48%) patients with PTCL, not otherwise specified, 63 (19%) with angioimmunoblastic T-cell lymphoma, 47(14%) with anaplastic large cell lymphoma (23 ALK-negative, 14 ALK-positive and 10 unknown), 12 (4%) with enteropathy-associated T-cell lymphoma, and others. The disease status at transplant in the allo-group was significantly worse than that in the auto-group (Table 1). The median number of chemotherapy regimens was 2 (range, 1–7), and the median duration between diagnosis and transplant was 267 days (range, 120-4889 days). The median follow-up for surviving patients was 45 mo (range, 2.3–141 mo). There was no significant difference in overall survival among different groups, including histological subtypes, RIC and myeloablative conditioning in the allo-group and high-dose chemotherapy regimens in the auto-group. Early survival rate after transplant was significantly better for auto-group than allo-group (Wilcoxon P=0.001), but the difference was marginal in the total course (Logrank P=0.06) (Figure). The non-relapse mortality (NRM) in the auto-group was significantly lower than that in the allo-group (P1), cell source (CB/BM+PB), and performance status (PS; >1), s